DALLAS / Oct 01, 2024 / Business Wire / Tenet Healthcare Corporation (NYSE: THC) today announced that it has completed the sale of its 70% majority ownership interest in Brookwood Baptist Health in Birmingham to Orlando Health consistent with previously disclosed terms.
The completed transaction includes five hospitals – Brookwood Baptist Medical Center, Citizens Baptist Medical Center, Princeton Baptist Medical Center, Shelby Baptist Medical Center, Walker Baptist Medical Center – and other related operations.
Tenet’s Conifer Health Solutions subsidiary has entered into a ten-year contract to provide comprehensive revenue cycle management services for these operations.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.
Last Trade: | US$157.62 |
Daily Change: | 0.38 0.24 |
Daily Volume: | 872,179 |
Market Cap: | US$15.100B |
July 24, 2024 April 30, 2024 February 08, 2024 December 13, 2023 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB